Cancer treatment and survivorship statistics, 2016 U.S. (open access) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, June 09, 2016

Cancer treatment and survivorship statistics, 2016 U.S. (open access)



open access

Treatment data are for cases diagnosed in the first 6 months of 2013 for all sites except testis, for which aggregated data from 2009 through 2013 were used because of the relatively small number of cases. In the 2013 NCDB data release, many common targeted therapy drugs are classified as chemotherapy. For this report, we also include drugs classified as immunotherapy in the chemotherapy category (chemotherapy does not include hormone therapy). For more information regarding drug classification categories, see the SEER-Rx Web site (seer.cancer.gov/tools/seerrx). Our analysis of treatment patterns does not include diagnostic procedures. Methods of drug delivery are not available in the NCDB, so topical or intravesical chemotherapy cannot be distinguished from systemic chemotherapy. More information can be found on the NCDB Web site (facs.org/cancer/ncdb).

Introduction

The number of cancer survivors continues to grow in the United States despite overall declining incidence rates in men and stable rates in women.[1] This reflects an increasing number of new cancer diagnoses resulting from a growing and aging population, as well as increases in cancer survival because of advances in early detection and treatment.
The American Cancer Society collaborates with the National Cancer Institute biennially to estimate the numbers of current and future cancer survivors to help the public health community better serve this unique population, some of whom must cope with long-term physical effects of treatment, as well as psychological and socioeconomic sequelae.[2] In this article, we use the term “cancer survivor” to describe any person who has been diagnosed with cancer, from the time of diagnosis through the remainder of his or her life. This includes patients currently undergoing treatment and those who may have become cancer-free. Throughout this article, the terms “cancer patient” and “survivor” are used interchangeably, although not all people with a history of cancer identify with the term “cancer survivor.” We provide

Conclusion

In this article, we document the continued growth of the cancer survivor population in the United States and describe patterns of treatment and common side effects across the most prevalent cancers. Despite increasing awareness of survivorship issues and the resiliency of cancer survivors, many challenges remain. These include a fractured health care system, poor integration of survivorship care between oncology and primary care settings, lack of strong evidence-based guidelines for posttreatment care, and financial and other barriers to quality care, particularly among the medically underserved. To address these challenges, ongoing efforts to identify best practices for the delivery of quality posttreatment cancer care are needed. Future research should also focus on identifying the best methods for encouraging cancer survivors to adopt and maintain a healthy lifestyle. Models for the integration of comprehensive care for cancer survivors, including self-management, wellness and healthy lifestyle promotion, and cancer rehabilitation, are beginning to emerge. As the evidence base grows, efforts at the individual, provider, system, and policy levels will help cancer survivors live longer and healthier lives.
estimates for the most prevalent cancers, as well as statistics on treatment patterns and survival and issues related to survivorship.

0 comments :

Post a Comment

Your comments?